In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

被引:126
作者
Barry, AL [1 ]
Fuchs, PC [1 ]
Brown, SD [1 ]
机构
[1] Inst Clin Microbiol, Wilsonville, OR 97070 USA
关键词
D O I
10.1128/AAC.45.6.1919-1922.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro activity of daptomycin is affected by the concentration of calcium cations in the test medium. Mueller-Hinton broth is currently adjusted to contain 10 to 12.5 mg of magnesium per liter and 20 to 25 mg of calcium per liter, but for testing of daptomycin, greater concentrations of calcium (50 mg/liter) are recommended to better resemble the normal concentration of ionized calcium in human serum. Two levels of calcium were used for broth microdilution tests of 2,789 recent clinical isolates of gram-positive bacterial pathogens. MICs of daptomycin were two- to fourfold lower when the broth contained additional calcium. For most species, however, the percentages of strains that were inhibited by 2.0 mug of daptomycin per mi were essentially identical with the two broth media. Enterococci were the important exception; i.e., 92% were inhibited when tested in calcium-supplemented broth but only 35% were inhibited by 2.0 mug/ml without the additional calcium. This type of information should be considered when selecting criteria for defining in vitro susceptibility to daptomycin.
引用
收藏
页码:1919 / 1922
页数:4
相关论文
共 10 条
[1]   INVITRO AND INVIVO ACTIVITY OF LY 146032, A NEW CYCLIC LIPOPEPTIDE ANTIBIOTIC [J].
ELIOPOULOS, GM ;
WILLEY, S ;
REISZNER, E ;
SPITZER, PG ;
CAPUTO, G ;
MOELLERING, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (04) :532-535
[2]   Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests [J].
Fuchs, PC ;
Barry, AL ;
Brown, SD .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (01) :51-58
[3]   ANTIMICROBIAL ACTIVITY AND SPECTRUM OF LY146032, A LIPOPEPTIDE ANTIBIOTIC, INCLUDING SUSCEPTIBILITY TESTING RECOMMENDATIONS [J].
JONES, RN ;
BARRY, AL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (04) :625-629
[4]   DAPTOMYCIN (LY146032) FOR PREVENTION AND TREATMENT OF EXPERIMENTAL AORTIC-VALVE ENDOCARDITIS IN RABBITS [J].
KENNEDY, S ;
CHAMBERS, HF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1522-1525
[5]   SUSCEPTIBILITY TESTING OF CLINICAL ISOLATES OF ENTEROCOCCUS-FAECIUM AND ENTEROCOCCUS-FAECALIS [J].
LOUIE, M ;
SIMOR, AE ;
SZETO, S ;
PATEL, M ;
KREISWIRTH, B ;
LOW, DE .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (01) :41-45
[6]   ACTIVITIES OF DAPTOMYCIN AND TEICOPLANIN AGAINST STAPHYLOCOCCUS-HAEMOLYTICUS AND STAPHYLOCOCCUS-EPIDERMIDIS, INCLUDING EVALUATION OF SUSCEPTIBILITY TESTING RECOMMENDATIONS [J].
LOW, DE ;
MCGEER, A ;
POON, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :585-588
[7]  
National Committee for Clinical Laboratory Standards, 2000, METH DIL ANT SUSC TE
[8]  
RAMAS MG, 1992, ANTIMICROB AGENTS CH, V36, P1864
[9]   PHARMACOKINETICS AND BACTERICIDAL RATES OF DAPTOMYCIN AND VANCOMYCIN IN INTRAVENOUS DRUG-ABUSERS BEING TREATED FOR GRAM-POSITIVE ENDOCARDITIS AND BACTEREMIA [J].
RYBAK, MJ ;
BAILEY, EM ;
LAMP, KC ;
KAATZ, GW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) :1109-1114
[10]  
Tally F P, 1999, Expert Opin Investig Drugs, V8, P1223, DOI 10.1517/13543784.8.8.1223